Nektar Therapeutics (NKTR)

04:37 AM

Nektar Therapeutics (NKTR) Stock Drops Amid Biotech Sector Volat - GuruFocus.com

04:37 AM

08:30 AM

J&J vet jumps to Affinia—Chutes & Ladders - Fierce Biotech

08:30 AM

Feb 06, 2025

Nektar Therapeutics Sees Unusually High Options Volume (NASDAQ:NKTR) - MarketBeat

Feb 06, 2025

Feb 06, 2025

Nektar Therapeutics announces senior leadership change - MSN

Feb 06, 2025

Feb 04, 2025

Nektar Names Kotzin Interim Chief Medical Officer - MarketWatch

Feb 04, 2025

Feb 04, 2025

Metastatic Melanoma Pipeline 2024: MOA and ROA Insights, - openPR

Feb 04, 2025

Feb 03, 2025

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol - Yahoo Finance

Feb 03, 2025

Jan 26, 2025

Nektar Therapeutics (NASDAQ:NKTR) Shares Purchased by HB Wealth Management LLC - Defense World

Jan 26, 2025

Jan 25, 2025

B. Riley Securities Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - MSN

Jan 25, 2025

Jan 25, 2025

JPMorgan Chase & Co. Buys 606,057 Shares of Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Jan 25, 2025

Jan 25, 2025

JPMorgan Chase & Co. Grows Position in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 25, 2025

Jan 22, 2025

Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan

Jan 22, 2025

Jan 18, 2025

Barclays PLC Purchases 175,596 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

Jan 18, 2025

Jan 17, 2025

Phase 2b study of rezpegaldesleukin for atopic dermatitis reaches target enrollment - Healio

Jan 17, 2025

Jan 17, 2025

Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08 - Defense World

Jan 17, 2025

Jan 16, 2025

B-Cell Lymphoma Clinical and Non-Clinical Studies, Key - openPR

Jan 16, 2025

Jan 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stake Lifted by Jane Street Group LLC - Defense World

Jan 15, 2025

Jan 13, 2025

LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times

Jan 13, 2025

Jan 13, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 13, 2025

Jan 11, 2025

Analysts Issue Forecasts for NKTR FY2024 Earnings - Defense World

Jan 11, 2025

Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study By Investing.com - Investing.com Australia

Jan 10, 2025

Jan 10, 2025

Nektar Therapeutics Completes Enrollment for Phase 2b REZOLVE-AD Trial of Rezpegaldesleukin - Dermatology Times

Jan 10, 2025

Jan 10, 2025

Nektar hits enrollment target for atopic dermatitis study - Investing.com India

Jan 10, 2025

Jan 10, 2025

Nektar Therapeutics (NKTR) competes target enrollment in its REZOLVE-AD Phase 2b study - StreetInsider.com

Jan 10, 2025

Jan 10, 2025

Nektar's Key Atopic Dermatitis Drug Trial Hits Full Enrollment Ahead of Schedule - StockTitan

Jan 10, 2025

Jan 09, 2025

Nektar Therapeutics to sell Alabama facility to Ampersand - MSN

Jan 09, 2025

Jan 09, 2025

B. Riley Upgrades Nektar Therapeutics (NASDAQ:NKTR) to Strong-Buy - MarketBeat

Jan 09, 2025

Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at B. Riley - MarketBeat

Jan 08, 2025

Jan 08, 2025

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Jan 08, 2025

Jan 08, 2025

Nektar stock positioned for growth as B. Riley forecasts REZPEG as key AD market disruptor - Investing.com India

Jan 08, 2025

Jan 07, 2025

B.Riley Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider.com

Jan 07, 2025

Jan 07, 2025

Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media? - Yahoo Finance

Jan 07, 2025

Jan 06, 2025

12 Best Penny Stocks to Invest in According to the Media - Insider Monkey

Jan 06, 2025

Jan 05, 2025

Numerous Nektar Therapeutics Insiders Sold Stock: Not A Positive Omen - Simply Wall St

Jan 05, 2025

Jan 04, 2025

Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership - Yahoo Finance

Jan 04, 2025

Dec 28, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 By Investing.com - Investing.com Nigeria

Dec 28, 2024

Dec 26, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Mark Andrew Wilson Sells 33,402 Shares - MarketBeat

Dec 26, 2024

Dec 26, 2024

Nektar Therapeutics chief legal officer sells shares worth $44,800 - Investing.com

Dec 26, 2024

Dec 21, 2024

Why Nektar Therapeutics May Be About to Take Off - AOL

Dec 21, 2024

Dec 21, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com - Investing.com Australia

Dec 21, 2024

Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Insider Sells $48,048.10 in Stock - MarketBeat

Dec 20, 2024

Dec 20, 2024

Nektar Therapeutics chief R&D officer sells $48,048 in stock - Investing.com

Dec 20, 2024

Dec 20, 2024

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024

Dec 19, 2024

Howard W. Robin Sells 46,995 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock - MarketBeat

Dec 19, 2024

Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock By Investing.com - Investing.com Australia

Dec 19, 2024

Dec 19, 2024

Nektar Therapeutics CEO Robin Howard sells $131,649 in stock - Investing.com India

Dec 19, 2024